Sagimet Biosciences plans Phase 3 acne trial for second half of 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Sagimet Biosciences plans Phase 3 acne trial for second half of 2026
(NASDAQ: SGMT) Delayed: 7.06 -0.04 (0.56%)
Previous Close $7.10    52 Week High $ 
Open $7.00    52 Week Low $ 
Day High $7.34    P/E N/A 
Day Low $7.00    EPS $ 
Volume 751,505